Real life evaluation of the multi-organ effects of Lumacaftor/Ivacaftor on F508del homozygous cystic fibrosis patients

BACKGROUND: Lumacaftor/Ivacaftor (LUM-IVA), a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector-potentiator combination, improves lung function and reduces pulmonary exacerbations (PEx) in F508del homozygous CF patients. However, the systemic effects of LUM-IVA outside the...

Descripción completa

Detalles Bibliográficos
Autores principales: Yaacoby-Bianu, Karin, Schnapp, Zeev, Koren, Ilana, Ilivitzki, Anat, Khatib, Mohamed, Shorbaji, Nadeem, Shteinberg, Michal, Livnat, Galit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585743/
https://www.ncbi.nlm.nih.gov/pubmed/36266606
http://dx.doi.org/10.1186/s40360-022-00624-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585743/
https://www.ncbi.nlm.nih.gov/pubmed/36266606
http://dx.doi.org/10.1186/s40360-022-00624-z

Ejemplares similares